Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer

Not Recruiting

Trial ID: NCT04389918


This study will find out if a meal replacement of this type is satisfying and tolerable for men with prostate cancer. Participants will receive meal replacements of TalityTM as their expected sole source of nutrition for 4 weeks. The purpose of the study is to test whether TalityTM Synthetic Meal Replacements are suitable to be used in larger studies of patients with prostate or other types of cancer.

Official Title

A Phase I Study of the Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Patients With Prostate Cancer

Stanford Investigator(s)

Randall Stafford
Randall Stafford

Professor of Medicine (Stanford Center for Research in Disease Prevention)

Alice C. Fan
Alice C. Fan

Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion Criteria:

   - Biopsy-proven prostate cancer with stable or rising PSA levels, defined as three
   consecutive PSA levels, each value greater than 1 week apart, with fluctuation between
   the three values no more than 10% downward. The third PSA needs to be within 30 days
   prior to enrollment and >= 0.1.

   - Patients may previously have been on any regimen of chemotherapy completed at least
   one month prior. Patients may be on any stable form of anti-androgen therapy.

   - Males >= age 18.

   - All patients must have a life expectancy of > 6 months.

   - Patients must have an ECOG Performance Status of <= 1

   - Patients must have no clinically significant abnormalities of organ or bone marrow

   - Patients must have the ability to understand and the willingness to sign a written
   informed consent document, and the willingness/ability to comply with the protocol

Exclusion Criteria:

   - Chemotherapy within one month prior to enrollment or plans to receive chemotherapy
   within one month after enrollment. Patients who are expected to require new or
   modified anti-androgen therapy during the course of the study are also excluded.

   - Patients may not be receiving any other Investigational Agents during the course of
   the study.

   - Patients who experience frequent symptoms of a gastrointestinal nature (e.g.,
   diarrhea, abdominal bloating, constipation or pain) are excluded.

   - Known CNS metastases.

   - Patients who, in the opinion of the Principal Investigator, have a clinically
   significant co-morbid disease that is likely to affect the ability of the patient to
   complete the trial, interfere with their ability with measurement of self-reported
   outcomes or result in adverse events unrelated to TalityTM are excluded.

   - Patients with a history of food allergy are excluded.

   - Concomitant medications necessary to treat baseline disorders are allowed (e.g.,
   hypertension, diabetes, and hyperlipidemia).

   - Patients requiring concomitant medications that, in the opinion of the Principal
   Investigator, have an unacceptable risk of adverse effects due to their nature (e.g.,
   anti-coagulant therapy, immuno-modulatory agents for autoimmune disease) must be

   - Pregnant or nursing patients will not be enrolled since prostate cancer is limited to

   - HIV-positive patients with active infections, HIV related cancer or poorly controlled
   viral loads must be excluded. HIV-positive patients who are stable on anti-viral
   therapy may be enrolled.


other: Tality

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Deirdre Crommie

New Trial Alerts

Receive email alerts when trials open to patients.